文献速递肺结节与肺癌

不确定肺结节风险分层的生物标志物研究进展

Update on Biomarkers for the Stratification of Indeterminate Pulmonary Nodules.
PubMed 文献 · Chest · 2023-05-25

本文综述了用于不确定肺结节风险分层的生物标志物研究进展。血液蛋白、液体活检、影像组学、呼出气挥发性有机物及气道/鼻上皮基因组分类器等生物标志物已被开发,但因缺乏改善患者结局的临床效用研究而少用于临床。

要点

  • 现有分层方法对中等概率结节欠佳,导致不必要的侵入性检查。
  • 多种生物标志物已开发,但需随机临床效用研究验证患者结局改善。

核心结论

  • 生物标志物有望辅助不确定肺结节的风险分层,但需随机临床效用研究证明改善患者结局后才能进入临床实践。

研究设计与样本

  • 本文为综述,未报告系统检索范围与样本量。

主要发现

  • 现有分层方法对中等概率结节欠佳,导致许多患者接受不必要的侵入性检查。
  • 已开发的生物标志物包括血液蛋白标志物、液体活检、影像组学、呼出气挥发性有机物及支气管或鼻上皮基因组分类器等。
  • 多数生物标志物缺乏临床效用研究,尚未整合进临床实践。

临床怎么用

  • 临床应认识到现有分层方法对中等概率结节的不足,避免不必要的侵入性检查。
  • 生物标志物目前尚未常规用于肺结节风险分层,需等待临床效用研究证据。

局限性

  • 本文为综述,未报告系统检索策略与纳入研究质量评价。
  • 多数生物标志物缺乏改善患者结局的随机临床效用研究证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lung cancer is the leading cause of cancer-related deaths. Early detection and diagnosis are critical, as survival decreases with advanced stages. Approximately 1.6 million nodules are incidentally detected every year on chest CT scan images in the United States. This number of nodules identified is likely much larger after accounting for screening-detected nodules. Most of these nodules, whether incidentally or screening detected, are benign. Despite this, many patients undergo unnecessary invasive procedures to rule out cancer because our current stratification approaches are suboptimal, particularly for intermediate probability nodules. Thus, noninvasive strategies are urgently needed. Biomarkers have been developed to assist through the continuum of lung cancer care and include blood protein-based biomarkers, liquid biopsies, quantitative imaging analysis (radiomics), exhaled volatile organic compounds, and bronchial or nasal epithelium genomic classifiers, among others. Although many biomarkers have been developed, few have been integrated into clinical practice as they lack clinical utility studies showing improved patient-centered outcomes. Rapid technologic advances and large network collaborative efforts will continue to drive the discovery and validation of many novel biomarkers. Ultimately, however, randomized clinical utility studies showing improved patient outcomes will be required to bring biomarkers into clinical practice.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Paez R, Kammer MN, Tanner NT, et al. Update on Biomarkers for the Stratification of Indeterminate Pulmonary Nodules. Chest. 2023. PMID: 37244587. doi:10.1016/j.chest.2023.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。